{"filings":[{"id":113912,"accession_number":"0001493152-26-009699","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Anixa holds annual meeting; re-elects four directors, approves say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Re-elected Kumar, Baskies, Gottschalk, Titterton as directors; each received 7.2M+ votes for.","Non-binding advisory vote on executive compensation passed with 6.0M for, 3.0M against.","Ratified Haskell & White LLP as independent auditor for FY ending Oct 31, 2026.","Presentation used at meeting furnished as Exhibit 99.1 but no text provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113911,"accession_number":"0001493152-26-005702","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anixa reports extended survival in ovarian cancer CAR-T trial; regulatory approval for 100x dose escalation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12 patients treated; 7 lived beyond expected median survival of 3-4 months; one survived 28 months.","No dose-limiting toxicities; protocol amended to escalate from 1x10^7 to up to 1x10^9 cells/kg (100x increase).","Next cohort includes lymphodepletion to potentially enhance CAR-T efficacy in solid tumors.","Three patients remain alive at 15, 14, and 8 months post-treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130319,"accession_number":"0001493152-25-027321","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anixa reports final Phase 1 breast cancer vaccine data: 74% immune response, safe, advancing to Phase 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vaccine met all primary endpoints; 74% of participants showed protocol-defined aLA-specific T cell responses.","Well tolerated at max tolerated dose; main adverse event was injection-site irritation; no flu-like symptoms.","Combination with Keytruda generated T cell responses without major additional side effects.","Enrolled 35 participants across three cohorts: early-stage TNBC, preventive mastectomy, adjuvant Keytruda.","Planning Phase 2 neoadjuvant combination study with Keytruda in newly diagnosed breast cancer patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183010,"accession_number":"0001493152-25-011151","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Anixa Biosciences annual meeting re-elects four directors, approves say-on-pay 66%-33%","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, Lewis Titterton re-elected as directors with 97-99% of votes cast.","Executive compensation approved on advisory basis: 6.6M for, 3.4M against (66% support).","Ratification of Haskell & White LLP as auditor for FY2025 passed with 19.9M for, 187k against.","Advisory vote on frequency of future say-on-pay: one-year option received 8.7M votes vs 1.1M for three years.","Broker non-votes totalled 10.5M shares on director elections and compensation proposals (32.7% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199584,"accession_number":"0001493152-24-044224","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anixa Biosciences presents updated positive Phase 1 data for breast cancer vaccine; Phase 2 planned for 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of alpha-lactalbumin vaccine updated at SITC; data continue positive trend across 3 cohorts.","Vaccine safe and well tolerated; only notable side effect was injection-site irritation.","Over 70% of patients exhibited protocol-defined immune responses (interferon-gamma, interleukin-17).","Combination with Keytruda (Cohort 1c) showed no major adverse events; one Grade 3 injection-site reaction in a recently lactated patient.","Phase 2 neoadjuvant study with randomized control planned to commence in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234980,"accession_number":"0001493152-24-018170","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Anixa expands Cleveland Clinic joint development to develop additional cancer vaccines","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anixa and Cleveland Clinic entered Joint Development and Option Agreement to develop vaccines for multiple cancers.","Anixa to pay non-refundable option fee and development funding in three tranches; first due May 8, 2024.","Option to obtain exclusive, royalty-bearing worldwide license to inventions developed under agreement.","Builds on existing breast cancer (Phase 1 TNBC) and ovarian cancer vaccine programs with Cleveland Clinic.","Research led by Dr. Thaddeus Stappenbeck and Dr. Justin Johnson at Cleveland Clinic."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252810,"accession_number":"0001493152-24-010995","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Anixa Biosciences re-elects four directors and ratifies auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. re-elected as directors with 7.9M-7.7M votes for.","Executive compensation approved on non-binding advisory basis: 6.0M for, 1.8M against, 123K abstain.","Haskell & White LLP ratified as independent auditor for FY ending Oct 31, 2024: 18.4M for, 80K against, 51K abstain.","Total shares present at meeting: 18,521,786 out of 31,711,753 eligible shares (58.4% turnout)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270290,"accession_number":"0001493152-23-043932","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anixa reports positive Phase 1 breast cancer vaccine data; T-cell responses in 75% of patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["16 TNBC patients treated; 12/16 (75%) developed antigen-specific T-cell responses at all dose levels.","Statistically significant increases in IFNγ (P=0.03) and IL-17 (P=0.0001) over baseline.","Dose Level 1 determined as immunologic and maximum tolerated dose; no serious adverse events besides injection site irritation.","Plans to evaluate vaccine with Keytruda in residual disease cohort and in BRCA/PALB2 mutation carriers.","CEO says data exceeded expectations; Phase 2/3 planning underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307376,"accession_number":"0001493152-23-012483","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anixa Biosciences and Cleveland Clinic report positive Phase 1 data for breast cancer vaccine","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of triple-negative breast cancer vaccine showed antigen-specific T cell responses at all dose levels.","Trial funded by U.S. Department of Defense; Anixa is exclusive worldwide licensee from Cleveland Clinic.","Participants were tumor-free women with history of TNBC, curatively treated, at high risk of recurrence.","Phase 1a study evaluates safety, MTD, and immune response; not designed to measure recurrence prevention."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326400,"accession_number":"0001493152-23-007172","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Anixa Biosciences stockholders re-elect four directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Dr. Amit Kumar (10.26M for, 940k withheld), Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton Jr.","Non-binding advisory vote on executive compensation passed: 9.17M for, 1.82M against, 221k abstain.","Ratified Haskell & White LLP as auditor for FY ending Oct 31, 2023: 20.44M for, 61k against.","Annual meeting held March 9, 2023; 20.97M shares represented out of 30.92M outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344111,"accession_number":"0001493152-22-034828","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anixa Biosciences reaches maximum tolerated dose in Phase 1a trial of breast cancer vaccine","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Maximum tolerated dose achieved in Phase 1a trial of preventative breast cancer vaccine.","Vaccine developed in collaboration with Cleveland Clinic.","Results presented at San Antonio Breast Cancer Symposium; press release and poster furnished."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360617,"accession_number":"0001493152-22-027121","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2022-09-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anixa Biosciences reports favorable safety and stable tumor lesions in first patient of CAR-T trial","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["First patient treated in chimeric endocrine receptor T-cell (CAR-T) clinical trial shows favorable safety signals.","Imaging at one month post-treatment indicates tumor lesions are stable and not growing.","Patient appears to be doing well and will continue to be monitored; enrollment continues.","Data presented by inventor Dr. Jose Conejo-Garcia at AACR/Rivkin Ovarian Cancer Symposium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360616,"accession_number":"0001493152-22-023285","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2022-08-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Anixa Biosciences doses first patient in Phase 1 CAR-T trial for ovarian cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1 trial of novel CER-T therapy for ovarian cancer at Moffitt Cancer Center.","Dose-escalation study to evaluate safety, maximum tolerated dose, and preliminary efficacy.","Trial targets follicle stimulating hormone receptor (FSHR) on ovarian cells.","Up to 48 patients may be enrolled in the study.","CER-T approach differs from traditional CAR-T by targeting an endocrine receptor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379717,"accession_number":"0001493152-22-010016","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2022-04-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Anixa promotes CFO/COO Michael Catelani to President; salary $434,512","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Catelani promoted to President effective April 14, 2022; retains roles as COO and CFO.","Annual base salary increased to $434,512; granted option to purchase 100,000 shares at closing price.","Stock option vests over 36 months, ten-year term, cashless exercise permitted.","Dr. Amit Kumar steps down as President but remains Chairman and CEO; no related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":397888,"accession_number":"0001493152-22-006637","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2022-03-11T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Anixa stockholders re-elect four directors, approve exec compensation, ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected directors Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. with between 8.4M and 9.2M votes for.","Non-binding advisory vote on executive compensation approved: 6,670,331 for, 2,450,849 against, 188,009 abstain, 9,914,423 broker non-votes.","Ratified appointment of Haskell & White LLP as auditor for FY ending Oct 31, 2022: 19,035,845 for, 193,874 against, 83,893 abstain.","Total shares present at meeting: 19,313,612 of 30,132,319 outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":416882,"accession_number":"0001493152-21-030965","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2021-12-09T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Anixa sets 2022 annual meeting for March 10; stockholder deadline Jan 10","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2022 Annual Meeting of Stockholders scheduled for Thursday, March 10, 2022, held virtually on the internet.","Stockholder proposals or director nominations must be received by January 10, 2022, per company bylaws.","Deadline set by Board as a reasonable time before printing and mailing proxy materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":416881,"accession_number":"0001493152-21-026636","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Anixa corrects board member's misstatement: DoD grant for breast cancer vaccine is $6.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Arnold Baskies misspoke on NBC10 Philadelphia about the Department of Defense grant supporting the breast cancer vaccine.","Correct grant amount is $6.2 million; the incorrect statement was unintentional.","Company filed Form 8-K to clarify the record under Regulation FD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":416880,"accession_number":"0001493152-21-024422","cik":715446,"company_name":"Anixa Biosciences Inc","ticker":"ANIX","form_type":"8-K","filed_at":"2021-10-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Anixa Biosciences begins patient recruitment for Phase I breast cancer vaccine trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient recruitment commenced Oct 1, 2021 for a preventative breast cancer vaccine developed with Cleveland Clinic and DoD.","Phase I open-label, dose-escalation trial in triple-negative breast cancer patients at high risk of recurrence.","Estimated 18–24 participants; trial expected to take approximately one year to complete.","Vaccine targets alpha-lactalbumin; details at ClinicalTrials.gov identifier NCT04674306."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":88848826.28205128,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}